Nasal polyps
Conditions
Interventions
Gold Standard:EPOS(The European Position Paper on Rhinosinusitis and Nasal Polyps)-based stratification of disease control.
learning 
model 
based 
on 
histopathology.
Sponsors
The Seventh Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Subjects must voluntarily participate in this research and abide by the research regulations, understand and voluntarily sign written informed consent; 2. Aged >= 18 years and <= 70 years; 3. There is no restriction on gender, but limited to Chinese; 4. The diagnostic criteria are based on the diagnostic criteria of nasal polyps in the Chinese Guidelines for the Diagnosis and Treatment of Chronic Sinusitis in 2018: (1) Subjective assessment of the patient: the patient has two or more symptom features, one of the necessary symptoms is nasal obstruction or nasal secretions, including postnasal drip, are often sticky and purulent, with or without facial pain or pressure, headache, and decreased or lost sense of smell. Symptoms that persist for 12 weeks or longer cannot be completely relieved; (2) Endoscopy: polyps are found in the nasal cavity or nasal passages, mucopurulent secretions can be seen in the middle nasal passages, with or without middle nasal passage edema or mucosal obstruction.
Exclusion criteria
Exclusion criteria: 1. Subjects have the following diseases: cystic fibrosis, congenital ciliary dyskinesia, non-invasive fungal ball and invasive fungal disease, systemic vasculitis and granulomatous disease, tumor patients, immunodeficiency and allergic fungal disease sinusitis; 2. Oral glucocorticoid treatment was used within 4 weeks before the test; 3. Subjects with other autoimmune diseases are receiving any one of glucocorticoids, leukotriene inhibitors and theophylline drugs for a long time through nasal, oral inhalation or systemic administration; 4. The subject is suffering from an upper respiratory tract infection, or less than one month after the upper respiratory infection; 5. There are clinically serious metabolic, cardiovascular, immune, neurological, blood, digestive, cerebrovascular or respiratory diseases, or any diseases that the researcher believes will interfere with the evaluation of the research results or affect the safety of the subjects; 6. Those who are currently participating in other clinical research or have participated in other clinical research within 30 days, or directly involved in this research; 7. History of mental illness, confrontational personality, bad motivation, suspiciousness, or other emotional or intellectual problems may affect the effectiveness of informed participation in research; 8. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the ROC(receiver operating characteristic) curve; | — |
Countries
China
Contacts
Public ContactSun Yueqi
The Seventh Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed